ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated Aug 2, 2026
ABBV — 11 winsABT — 12 wins
Price Performance
ABBV +27.26%ABT -18.65%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | +0.64% | +15.06% |
| 3 Months | +19.57% | +16.82% |
| 6 Months | +14.63% | +0.01% |
| YTD | +10.58% | -15.35% |
| 1 Year | +33.47% | -17.15% |
| 3 Year | +78.07% | -6.08% |
| 5 Year | +113.79% | -10.31% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | +9.4% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -14.9% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 123.90 | 29.54 |
| Forward P/E | 18.46 | 18.73 |
| PEG Ratio | 7.48 | 3.24 |
| P/S Ratio | 7.29 | 3.98 |
| P/B Ratio | 16.66 | 2.72 |
| EV/EBITDA | 29.95 | 21.28 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.04 | $3.59 |
| Gross Margin | +83.54% | +56.28% |
| Operating Margin | +31.56% | +16.50% |
| Net Margin | +4.66% | +9.65% |
| ROE | +13.23% | +9.50% |
| ROA | +2.67% | +5.07% |
| Debt/Equity | 2.65 | 0.52 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +12.43% | +7.78% |
| Revenue Growth QoQ | -9.72% | -2.57% |
| EPS Growth YoY | -45.83% | -18.24% |
| EPS Growth QoQ | -61.76% | -39.22% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 57.52 | 68.91 |
| % From 20-Day SMA | -0.46% | +7.04% |
| % From 50-Day SMA | +6.13% | +13.67% |
| % From 200-Day SMA | +12.46% | -2.21% |
| % From 52-Week High | -5.53% | -22.52% |
| % From 52-Week Low | +34.67% | +29.39% |
Analyst Ratings
ABBV
Buy(28 analysts)
Strong SellHoldStrong Buy
Price Target
$279.50
+10.62% upside
ABT
Buy(28 analysts)
Strong SellHoldStrong Buy
Price Target
$123.00
+15.97% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $458.11B | $179.58B |
| Shares Outstanding | 1.77B | 1.74B |
| Avg Volume (10D) | 5.46M | 11.08M |
| Dividend Yield | 2.63% | 2.41% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 23 comparable metrics, ABT leads in 12 categories while ABBV leads in 11. ABT has a consensus analyst rating with 28 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +33.47% compared to ABT's -17.15%. In the short term (1 month), ABBV returned +0.64% vs ABT's +15.06%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 123.90 compared to ABT's 29.54. On a price-to-sales basis, ABBV trades at 7.29x vs ABT's 3.98x. Forward P/E: ABBV at 18.46 vs ABT at 18.73.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +12.43% year-over-year compared to ABT's +7.78%. EPS growth: ABBV at -45.83% vs ABT at -18.24%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 2.63%. ABT pays a dividend with a yield of 2.41%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 28 analysts with a target price of $279.50 (+10.62% upside). ABT has 28 analysts with a target of $123.00 (+15.97% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.